Skerjanec Simona 4

What Happened Simona Skerjanec, a director of IMMUNIC, Inc. (IMUX), was granted an award recorded as 25,370 derivative shares on June 29, 2026. The filing shows an acquisition price of $0.00 and a reported monetary value of $0 because the transaction represents options (a derivative award), not an open‑market purchase or sale.

Key Details

• Transaction date: 2026-06-29 (reported same day).
• Instrument: Derivative (options to purchase 25,370 shares); filing shows $0.00 acquisition price and $0 reported value.
• Vesting/status: The options were fully vested as of March 27, 2026 (footnote F2).
• Condition: The grant was conditionally approved by the Board on March 27, 2026 and became effective following stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan at the company’s June 29, 2026 annual meeting (footnote F1).
• Shares owned after transaction: Not specified in the provided filing details.
• Timeliness: Filing date and transaction date are both 2026-06-29, indicating the report was filed promptly.

Context This was a derivative award (options) rather than an outright purchase or sale. Because the filing records options and not exercised shares, there was no immediate cash paid or proceeds received and no immediate sale of shares. Such grants are common for directors and are informative about compensation but do not by themselves indicate buying or selling intent in the market.